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Objective: This study was undertaken to investigate the possible negative effect of -blockers on skin microcirculation in
patients with intermittent claudication and hypertension.
Methods and materials: In this clinical crossover study, 20 patients with mild to moderate hypertension, treated with
long-term -blockade, and intermittent claudication or ischemic rest pain, underwent assessment of peripheral circula-
tion before and after 2-week withdrawal of -blocking therapy and again 2 weeks after restarting therapy. Replacement
therapy (calcium antagonist) was given if considered necessary to control hypertension. Skin microcirculation was
assessed with three noninvasive techniques: capillary microscopy of the hallux nailfold, transcutaneous oximetry of the
forefoot, and laser Doppler fluxmetry of the great toe.
Results: Mean initial blood pressure was 163/81 mm Hg. Mean heart rate significantly increased with withdrawal of
-blocker, from 65 bpm to 85 bpm. No significant differences in skin microcirculation and blood pressure were found
between measurements obtained before, during, and after withdrawal of -blocking therapy. Patients experienced no
change in symptoms during the study.
Conclusion: -Blockers do not appear to have a negative effect on peripheral skin microcirculation and are therefore not
contraindicated to treat hypertension when intermittent claudication or ischemic rest pain is also present. (J Vasc Surg
2003;38:535-40.)
Arteriosclerosis is a common generalized disease. For
this reason, hypertension, peripheral vascular disease, and
coronary artery disease are often seen in combination with
each other. Of patients with hypertension, 2% to 5% have
intermittent claudication, which increases with age. Simi-
larly, 35% to 55% of patients with peripheral vascular disease
also have hypertension.1 Hence hypertension frequently is
treated with a -adrenergic blocking agent (-blocker)
when peripheral vascular disease also is present, usually in
the form of intermittent claudication.
Aggravation of intermittent claudication has been
claimed to be a side effect of -blockade. Despite findings
of some controlled studies, uncertainty about this subject
remains. Several case reports have described adverse effects
of -blockers, such as cold extremities, Raynaud phenom-
enon, or peripheral ischemia.2-4 A meta-analysis of 11
randomized controlled trials published in 1991 concluded
that -blockers, both selective and nonselective, have no
significant effect on pain-free walking distance and perfu-
sion of the calf muscles.5 Also, other smaller studies re-
ported that the symptoms of claudication are not worsened
by -blockers.4 During the same period, some studies
reported a decrease in walking distance and ankle-brachial
index (ABI) associated with use of various -blockers,
including atenolol, labetalol, metoprolol, pindolol, and
propranolol.6,7
Most studies of the effect -blockers in patients with
peripheral vascular disease assessed the macrocirculation or
the symptoms of intermittent claudication. Microcircula-
tory effects of -blockers have been insufficiently investi-
gated, while the local microcirculatory perfusion of the calf
muscles and foot skin are ultimately responsible for the
symptoms of peripheral vascular insufficiency. In addition,
preservation of the microcirculation of the skin is essential
for a good prognosis.8 Only a few studies have investigated
the local microcirculation, and these studies focused only
on the effect of -blockers in healthy subjects9 or in pa-
tients with hypertension without leg ischemia, and investi-
gated the microcirculation in the skin of the fingers.10 Only
in one small, unblinded study comprising 11 previously
untreated patients with hypertension and intermittent clau-
dication, skin microcirculation was studied with laser
Doppler and transcutaneous partial oxygen pressure
(tcpO2) measurements before and after 1 month of treat-
ment with bisoprolol (1-selective) or lisinopril (angioten-
sin converting enzyme [ACE] inhibitor). A slight tendency
toward decreased microcirculatory perfusion was noted
with bisoprolol therapy.11
To determine the possible effects of -adrenergic
blocking drugs on peripheral skin microcirculatory blood
flow in arteriosclerotic peripheral vascular disease, we as-
sessed the influence of chronic -blocking therapy on skin
microcirculation in the feet of patients with moderate to
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severe peripheral vascular disease and uncomplicated hy-
pertension treated with a -blocker.
METHODS
Patients with hypertension, treated with a -blocker,
and with chronic intermittent claudication (Fontaine stage
2, Rutherford grade I) or ischemic rest pain (Fontaine stage
3, Rutherford grade II) were screened in the outpatient
clinics of the departments of vascular surgery, internal
medicine, and cardiology. Hypertension was defined as
blood pressure above 140/95 mm Hg, as determined by
the treating cardiologist. Patients were included or ex-
cluded according to the criteria presented in Table I. Use of
cardioselective -blockers was allowed, because of the un-
certain effect on peripheral circulation.12 The local medical
ethics committee agreed to the study, under the condition
that the cardiologist would be consulted to determine
whether -blocker could be stopped for 2 weeks and
whether replacement therapy was indicated. Inclusion of
patients with ischemic tissue loss (Fontaine stage 4, Ruth-
erford grade III) was not deemed ethical, because early
revascularization would likely be necessary. Informed con-
sent was obtained from all patients before participation in
the study.
Study design. In patients who met inclusion criteria,
the cardiologist was asked to judge whether temporary
withdrawal of -blocking therapy was feasible and whether
replacement medication was necessary. The investigation
sequence is illustrated in Fig 1. After the first assessment of
skin microcirculation in the most ischemic leg, the patient
was instructed to gradually phase out the -blocker by
taking half the dosage for 3 days before stopping com-
pletely for 2 weeks. After consulting the cardiologist, 6 of
19 patients were prescribed the calcium antagonist amlo-
dipine as replacement drug for the 2-week period, because
possible elevation in blood pressure without the -blocker
was considered unacceptable. Amlodipine was deemed to
not have a similar influence on peripheral circulation.
The microcirculatory investigation was repeated, after
which the -blocker was continued. After another 2 weeks
the microcirculatory measurements were performed a third
time. Measurements were performed in a room with the
temperature controlled at 22°C  1°C.
Patients served as their own controls, and any effect of
the -blocker on the peripheral microcirculation should be
absent at the second measurement and reappear at the third
measurement. The severity of chronic peripheral vascular
disease in these patients was not likely to change during the
4-weeks study.
Investigation techniques. Three techniques were
used to assess the various functional layers of skin microcir-
culation: capillary microscopy, transcutaneous oxygen pres-
sure and laser Doppler measurements. These are noninva-
sive and reproducible methods of assessing severity of
peripheral vascular disease by appreciating the local micro-
circulatory perfusion and oxygenation of the skin.13-16
Capillary microscopy. Capillary microscopy enables
investigation of the nutritional status of the skin in patients
with peripheral arterial occlusive disease.16 It appreciates
both capillary anatomy and erythrocyte velocity in the
nailfold of the great toe. The method and equipment used
have been described in detail.13 In brief, the system consists
of a microscope with incident illumination (Leitz POL-
cube; Leica Microsystems, Ry¨swy¨k, The Netherlands) from
a mercury lamp. The images obtained are projected onto a
camera, visualized on a television monitor, and stored on
tape for offline analysis.
The patients were examined in the sitting position, to
ensure maximal filling of the vessels, so that the toe could
be placed under the microscope. The foot was fixed with
clay to prevent movement artifacts. After appreciation of
capillary density (number of capillary loops visible per
square millimeter of nailfold skin), capillary erythrocyte
perfusion was measured in at least two capillaries. This was
assessed before (resting velocity; in m/s) and after tem-
porary occlusion (peak velocity; in m/s) with 1-minute
inflation of a cuff around the ankle. In addition, time to
peak velocity (in seconds) was measured. This hyperemic
response can be regarded as a measure of the microvascular
reserve capacity.
Transcutaneous oximetry. The oxygen delivered by
local microcirculation to the skin surface was evaluated with
a device (TCM3; Radiometer, Copenhagen, Denmark)
that measured tcpO2 with a heated surface (Clark-type)
electrode.13
With the patient supine, the electrode used to measure
tcpO2 was attached to the dorsum of the foot in the first
intermetatarsal space with an adhesive fixation ring contain-
ing contact liquid. The electrode was warmed to 44°C to
attain maximum vasodilatation locally. Partial oxygen pres-
sure (pO2) at rest (in mm Hg) was recorded for at least 10
minutes. When the curve had reached a stable value, arterial
occlusion for 3 minutes was accomplished by inflating a cuff
around the ankle. Recording was continued until the curve
reached its hyperemic peak (in mm Hg). In addition, time
to peak pO2 (in seconds) was measured.
Laser Doppler fluxmetry. With this technique (Peri-
flux Pf4000; Perimed, Stockholm, Sweden), infrared laser
light with a wavelength of 780 nm is conducted through
optical fibers to the skin, where it penetrates to a depth of 1
to 1.5 mm and is partly reflected. This light, when back-
Table I. Inclusion and exclusion criteria
Inclusion criteria
Chronic peripheral arterial disease: Fontaine stages 2b or 3,
Rutherford grade II or I, category 2 or 3.
Hypertension treated with a -blocker.
Ankle-brachial blood pressure index 90% or 50% after
exercise, or toe pressure 50 mm Hg.
Painfree walking distance 250 m.
Exclusion criteria
Withdrawal or change of -blocking therapy contraindicated
because of coronary disease, heart failure, renal insufficiency,
or arrhythmia.
Planned vascular surgical intervention during study period.
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scattered by moving objects (erythrocytes), undergoes a
frequency shift proportional to the velocity and number of
moving objects, and is expressed in arbitrary units (volts)
and referred to as flux.13 It appreciates total, mainly ther-
moregulatory, skin perfusion.
The laser Doppler probe holder was attached to the
dorsal side of the great toe with double-sided-adhesive
tape. This site was chosen because in this area arteriolove-
nular anastomoses involved in thermoregulation are nu-
merous. To avoid flux variation due to rotation of the
probe, it was secured to the holder with adhesive tape. The
probe cable was suspended to prevent the probe exerting
pressure on the skin. After reaching a stable recording, flux
at rest (in volts) was measured, and subsequently the reac-
tive hyperemic response, yielding peak flux (in volts) and
time to peak flux (in seconds), was induced simultaneously
with tcpO2 measurement. Biologic zero, that is, the laser
Doppler value, as registered during arterial occlusion and
which is not due to blood movement, was subtracted from
the other flux values.
Laser Doppler and tcpO2 measurements were recorded
with a data acquisition and analysis system (AcqKnowledge
III and MP 100WSW; Biopac Systems, Santa Barbara,
Calif).
Systolic and diastolic blood pressure and heart rate were
measured with the patient supine, with a Dynamap Vital
Signs Monitor 8720 (Johnson & Johnson, Tampa, Fla).
Three measurements were obtained during the investiga-
tive session, and their mean value was used for analysis. ABI
was taken from the medical record if it was a recent mea-
surement (within 7 months, provided no intervention had
taken place in the meantime). If a recent measurement was
not available, ABI was measured during the same session,
with an ankle cuff and an 8 MHz Doppler scanning probe.
All patients were asked about walking-induced pain and
well-being during periods of withdrawal and resumption of
-blocking therapy. Each measurement session lasted
about 40 minutes.
Power and statistical analysis. If the peripheral cir-
culation can indeed be influenced negatively by -blockers,
withdrawal of -blocking therapy should bring improve-
ment in macrocirculation and microcirculation. On the
basis of earlier results, a change from moderate to mild
ischemia is accompanied by improvement in the capillary
hyperemic response, from 20 m/s to 40 m/s (SE, 15
m/s).13 When expecting a similar difference as a result of
-blocking therapy, 20 patients are needed ( 0.05; 1
0.80). With the laser Doppler hyperemic perfusion param-
eter, an increase from 8 V (moderate ischemia) to 17 V
(mild ischemia) (SD, 8 V) was observed, which leads to a
comparable number of patients required.
Data for microcirculatory measurements were inter-
preted in blinded fashion by a second investigator after all
patients were examined. Differences between results of the
three investigative sessions were analyzed with the nonpara-
metric Friedman test, because the data were likely to be
unevenly distributed. A paired statistic (Wilcoxon test) was
used to compare the results with and without -blocker
therapy.
RESULTS
Of the 20 patients included, 19 patients completed the
study. One patient died during the study, due to an unde-
tected abdominal aorta aneurysm. Thus the final patient
group consisted of 9 women and 10 men, with mean age of
65 years (range, 44-82 years). The prevalence of risk factors
for vascular disease in the 19 patients was as follows: hyper-
cholesterolemia, scored if the patient received any lipid-
lowering drug, 9 patients (47%); present smoker, 9 patients
(47%); type II diabetes, 7 patients (37%); positive family
history, 7 patients (37%).
Of the 19 patients, 14 had intermittent claudication
and 5 had ischemic rest pain. Average pain-free walking
distance was 69 m (range, 20-170 m); mean ABI was 56%.
In all patients hypertension was treated adequately; mean
systolic and diastolic blood pressure was 163 and 81 mm
Hg, respectively. Mean heart rate was 65 bpm during
-blocker treatment. Other than the -blocker, 74% of
patients used other antihypertensive medications (Table
II). -Blockers were used for a mean of 6.5 years.
Results of the microcirculatory investigations, and
blood pressure and heart rate measurements are depicted in
Table III. A typical laser Doppler recording and tcpO2
measurement is shown in Fig 2.
No significant differences (P  .05) were found in
systolic and diastolic blood pressure between the three
measurement sessions (Table III). This was also true in
patients who did not receive amlodipine as replacement
therapy. Heart rate at the second measurement was signif-
icantly higher (P  .001) than at the first and third mea-
surements, illustrating patient compliance to stop using the
Fig 1. Schema of -blocker use and investigation sequence during the study.
JOURNAL OF VASCULAR SURGERY
Volume 38, Number 3 Ubbink et al 537
-blocker. Microcirculatory parameters did not improve
significantly after withdrawal of -blocker therapy.
Five of 19 patients experienced improvement of symp-
toms after withdrawal of -blocker. Walking distance had
increased subjectively, complaints about cold feet had di-
minished, or pain had declined. These improvements dis-
appeared after resumption of -blocker. In these patients
no apparent trend toward change in skin microcirculation
was observed. In 1 of these patients the vascular surgeon
decided, after the study and without knowledge of mea-
surement results, to replace metoprolol with amlodipine.
Two patients had more complaints after stopping the
-blocker. In 1 of these patients symptoms had progressed
even at the third measurement. In the other patient edema
developed with amlodipine therapy. The remaining 12
patients did not notice any change during withdrawal or
resumption of -blocker therapy.
Results in patients given metropolol did not differ from
those in patients given atenolol. In addition, no differences
were found between patients with intermittent claudication
and those with ischemic rest pain.
DISCUSSION
Current opinion as to whether use of -blockers is
contraindicated in peripheral arterial disease seems depen-
dent on severity of the disease. Some authors believe that
-blockers should not be used only in those patients with
ischemic rest pain or tissue loss, but can be prescribed in
patients with mild or moderate ischemic disease, if careful
surveillance is performed to discern any changes in symp-
toms related to intermittent claudication. The present find-
ing that skin microcirculation did not change with or
without long-term -blocking therapy leads to the conclu-
sion that -blockers have no substantial adverse effect on
peripheral perfusion in these patients. This is corroborated
by existing evidence that suggests that the initially increased
vascular resistance may decrease after long-term -blocking
therapy.17
The alleged aggravation of symptoms of peripheral
vascular disease by -blockade was thought to be caused by
induction of reflex vasoconstriction of the peripheral ves-
sels, although -blockers with intrinsic sympaticomimetic
activity appear to result in less diminution of cardiac output
and should therefore reduce this adverse effect.18 Second,
-blockade may decrease fat metabolism, which second-
arily increases use of carbohydrates, resulting in earlier
hypoglycemia and depletion of muscle glycogen, with sub-
sequent reduction in working capacity.19 This may explain
the subjective effect sometimes found after cessation of
-blocker therapy. However, the subjective effects ob-
served in this study are difficult to interpret, because the
patients were not blinded to the treatment protocol. Know-
ing that the -blocker was stopped for awhile may well have
influenced subjective symptoms.
Cardioselective properties of a -blocker (eg, metopro-
lol) should also reduce any side effects on peripheral circu-
lation. However, cardioselectivity is dose-dependent, based
on in vitro pharmacologic testing, which is difficult to
extrapolate to human beings, especially persons with dis-
ease. Furthermore, no tissue possesses a single type of
-adrenoceptor, but merely a preponderance of one sub-
group.12 Hence we did not exclude patients using cardio-
selective -blockers.
In the present study, microcirculatory techniques were
used to appreciate skin microcirculation in the foot whereas
patients with intermittent claudication (most of our pa-
tients) have ischemic pain in the calf muscles during exer-
cise. Nevertheless, differences in skin perfusion exist be-
tween patients with claudication or ischemic rest pain and
asymptomatic control subjects.13,20 Furthermore, capillary
microscopy, as well as transcutaneous oximetry and laser
Doppler fluxmetry have been used successfully in studies of
the effect of -blockers on the microcirculation.9-11,21
Hence it is plausible that local disturbances in skin micro-
circulation reflect the effect of macrocirculatory leg isch-
emia, which affects both muscle and skin microcirculation.
The presence of patients with both claudication and
ischemic rest pain, as well as comorbid conditions and risk
factors (eg, diabetes, hyperlipidemia, smoking), could have
caused some heterogeneity in the results. However, pa-
tients were selected to provide a clinically relevant patient
group. In a previous study the local microcirculation
showed disturbances in both patients with claudication and
with rest pain.13 The effect of diabetes appears to be
outweighed by the effect of generalized atherosclerosis on
peripheral skin microcirculation.22 A different response to
-blockers among these subgroups is unknown. In this
study, all patients served as their own control, and should
have shown improvement in local microcirculatory param-
eters after cessation of -blocker if it indeed had any sub-
stantial effect.
To demonstrate any effect, -blocking therapy was
interrupted for 2 weeks, because the effect of -blockers
disappears within 2 weeks after withdrawal.23 That brady-
cardia had disappeared by the time of the second measure-
ment supports this. The significant increase in heart rate
after 2 weeks of withdrawal is in agreement with other
studies.23
In this study the 4-week interval between the three
different measurements might have induced differences
Table II. Antihypertensive medication used
Medication*
No. of patients




ACE Inhibitors 11 58
Diuretic agents 11 58




ACE, angiotensin converting enzyme.
*Five patients used only a -blocker; 5 patients used one, 6 patients used
two, and 3 patients used three additional antihypertensive drugs.
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due to factors such as physical and mental stress, nicotine
and coffee use, and temperature variation. If these factors
already masked the effect of -blocker therapy, then the
possible adverse effect of this therapy has a lesser role.
Significant progression of chronic peripheral arterial disease
also was not likely in this time span. Only 1 patient reported
worsening of symptoms during both follow-up sessions,
which might have been due to progression of disease.
Concomitant medication used, in particular, ACE in-
hibitors and diuretic agents, may have caused a vasodilatory
effect and may have masked any effect of -blocker. How-
ever, the vasodilator effect of thiazides is small and occurs
only at high concentrations.24 Unlike -blockers, ACE
inhibitors do not interfere with the normal hemodynamic
responses to stress or exercise, and blood pressure reduc-
tion is maintained.25
Some patients were prescribed amlodipine as replace-
ment drug. Any peripheral dilating effect of replacement
amlodipine could have improved skin microcirculation dur-
ing interruption of -blocker therapy and thus give the false
Table III. Investigation results
Session 1 Session 2 Session 3
P*Median IQR Median IQR Median IQR
Blood pressure (mm Hg)
Systolic 156 138-191 156 148-179 143 124-178 .146
Diastolic 80 75-88 80 76-96 76 74-82 .071
Heart rate (bpm) 65 59-69 85 74-93 65 58-75 .000
Laser Doppler fluxmetry
Rest flux (V) 0.108 0.473-0.233 0.141 0.047-0.457 0.151 0.044-0.309 .779
Peak flux (V) 0.525 0.432-0.870 0.905 0.443-1.198 0.696 0.230-1.046 .829
Time to peak (s) 49.5 34.2-104.2 48.4 35.8-58.0 61.0 37.4-73.3 .472
Peak flux  Rest flux (V) 0.401 0.289-0.567 0.396 0.265-0.845 0.350 0.142-0.644 .444
Transcutaneous oximetry (tcpO2)
Rest 50.7 36.4-57.2 50.9 47.8-56.7 47.8 43.0-57.1 .305
Peak 52.3 41.9-60.0 54.6 51.4-59.0 50.9 48.6-59.2 .472
Time to peak pO2 2.99 2.49-3.78 3.07 2.67-3.58 3.27 2.67-3.94 .936
Capillary microscopy
Density 86 77-125 94 80-104 85 72-111 .155
Rest velocity (m/s) 25 5.8-46 40 2.0-75 40 25-130 .074
Peak velocity (m/s) 50 29-109 80 49-175 70 55-206 .292
Time to peak (s) 28 20-38 23 16-30 30 18-36 .128
*Friedman test.
IQR, Interquartile range.
Fig 2. Typical laser Doppler recording (upper panel) and transcutaneous partial oxygen pressure tracing (lower panel)
at rest, during arterial occlusion, and during reactive hyperemia.
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impression that -blockers have a negative effect on the
microcirculation. Even so, it is not likely that this influ-
enced our results, because only a small number of patients
received amlodipine replacement therapy. In other studies
no significant effect was observed on laser Doppler and
capillary perfusion studies by amlodipine in patients with
untreated mild to moderate essential hypertension.26,27 On
the other hand, in one of our patients edema developed due
to amlodipine replacement, which is a known cause of
diminution of peripheral perfusion as a result of tissue
pressure.
In conclusion, on the basis of this clinical crossover
study, -blockers are not contraindicated to treat hyperten-
sion when intermittent claudication or ischemic rest pain is
also present. Especially in patients with angina pectoris and
hypertension, -blockers remain the therapy of choice.
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